Where Regenxbio Stands With Analysts
Portfolio Pulse from Benzinga Insights
Regenxbio (NASDAQ:RGNX) has received varied opinions from 4 analysts over the past quarter, all of which are bullish. The average 12-month price target is $38.25, reflecting a 2.46% increase from the previous target. Key analysts from HC Wainwright & Co. and Goldman Sachs have maintained or raised their buy ratings. Regenxbio, a biotechnology company, has shown solid revenue growth but faces challenges with lower growth rates compared to peers. The company maintains strong financial metrics with a balanced debt approach.

August 05, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio has received bullish ratings from 4 analysts, with an average price target of $38.25, reflecting a 2.46% increase. Analysts from HC Wainwright & Co. and Goldman Sachs have maintained or raised their buy ratings. The company has shown solid revenue growth but faces challenges with lower growth rates compared to peers.
The unanimous bullish ratings and increased price targets from key analysts suggest positive sentiment towards Regenxbio. The company's solid revenue growth and strong financial metrics further support a likely positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100